Paranta Biosciences Limited is an unlisted Australian biopharmaceutical company developing PB01 as a first-in class biotherapeutic for the prevention of delayed graft function during kidney transplantation.
PB01, Paranta’s unique recombinant form of human follistatin-288, binds to and inhibits members of the TGF-β superfamily of cytokines, where it modulates the resulting inflammation, fibrosis and metabolic effects.
Paranta was established with the aim of commercializing property based on pioneering research by Monash University on follistatin. This initial research has been pivotal for Paranta's selection & subsequent clinical development of PB01. Paranta has advanced from the discovery to development phase and is now focused on acute kidney injury.
Paranta Biosciences has strong and active collaborative relationships with the Hudson Institute of Medical Research (previously Monash Institute of Medical Research), Monash University and affiliated medical and pharmaceutical institutes.
The intellectual founding father of Paranta Biosciences who led the medical research team that first isolated follistatin and performed pioneering research on the structure, physiology and role of inhibins, activins and follistatin.
Professor David M. de Kretser
Paranta Biosciences corporate timeline
Since the company commenced operations in 2011, we have reached many key milestones. Click through to see some of our major achievements.
Transitioned from Discovery to Development Phase company.
Focus on developing current formulation of PB01 for preventing delayed graft function during kidney transplantation.
Positive preclinical results in models of chronic kidney disease.
US and European patents granted, covering organ transplantation.
US Cystic Fibrosis Foundation Therapeutics Development Award.
PB01 (inhaled) Phase 1 LPS challenge clinical trial completed in the UK. Safety & tolerability established in healthy volunteers.
PB01 (inhaled) phase 1 SAD / MAD clinical trial completed. Safety and tolerability established in healthy volunteers.
Paranta manufactures the first cGMP batch of PB01.
PB01 (i.v.) kidney disease research collaboration established with McMaster University, Canada.
Preclinical safety & toxicology studies for inhaled PB01 undertaken in Canada.
Positive preclinical results in ischemia reperfusion injury (IRI) model of organ transplantation.
Efficacy established in preclinical models of lung disease.
Follistatin is discovered.